Toronto Dominion Bank raised its stake in Regeneron Pharmaceuticals Inc (NASDAQ:REGN) by 57.4% during the first quarter, Holdings Channel reports. The fund owned 20,540 shares of the biopharmaceutical company’s stock after buying an additional 7,487 shares during the period. Toronto Dominion Bank’s holdings in Regeneron Pharmaceuticals were worth $7,958,000 as of its most recent filing with the SEC.
Other institutional investors have also bought and sold shares of the company. Korea Investment CORP boosted its position in Regeneron Pharmaceuticals by 223.9% in the first quarter. Korea Investment CORP now owns 298 shares of the biopharmaceutical company’s stock worth $115,000 after buying an additional 206 shares during the last quarter. WFG Advisors LP boosted its position in Regeneron Pharmaceuticals by 12,358.3% in the fourth quarter. WFG Advisors LP now owns 7,475 shares of the biopharmaceutical company’s stock worth $119,000 after buying an additional 7,415 shares during the last quarter. Alpha Windward LLC boosted its position in Regeneron Pharmaceuticals by 4.4% in the first quarter. Alpha Windward LLC now owns 383 shares of the biopharmaceutical company’s stock worth $148,000 after buying an additional 16 shares during the last quarter. Live Your Vision LLC purchased a new position in Regeneron Pharmaceuticals during the third quarter worth about $157,000. Finally, Blenheim Capital Management BV purchased a new position in Regeneron Pharmaceuticals during the fourth quarter worth about $160,000. Institutional investors and hedge funds own 68.83% of the company’s stock.
Shares of Regeneron Pharmaceuticals Inc (NASDAQ:REGN) traded down 1.60% on Friday, hitting $450.01. The stock had a trading volume of 996,846 shares. The company has a market cap of $47.51 billion, a P/E ratio of 54.47 and a beta of 1.44. Regeneron Pharmaceuticals Inc has a 52-week low of $325.35 and a 52-week high of $462.96. The company has a 50-day moving average of $397.84 and a 200-day moving average of $380.88.
Regeneron Pharmaceuticals (NASDAQ:REGN) last announced its earnings results on Thursday, May 4th. The biopharmaceutical company reported $2.92 earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of $2.50 by $0.42. Regeneron Pharmaceuticals had a return on equity of 22.51% and a net margin of 18.10%. The business had revenue of $1.32 billion during the quarter, compared to analyst estimates of $1.30 billion. During the same quarter in the previous year, the business earned $2.57 earnings per share. The company’s revenue for the quarter was up 9.8% compared to the same quarter last year. On average, equities analysts anticipate that Regeneron Pharmaceuticals Inc will post $12.67 EPS for the current fiscal year.
ILLEGAL ACTIVITY NOTICE: This article was originally published by Mideast Time and is the property of of Mideast Time. If you are reading this article on another site, it was illegally stolen and republished in violation of U.S. and international trademark & copyright law. The legal version of this article can be viewed at https://www.mideasttime.com/toronto-dominion-bank-has-7-958-million-stake-in-regeneron-pharmaceuticals-inc-regn/1707976.html.
A number of equities analysts have recently issued reports on the company. Leerink Swann set a $448.00 price objective on Regeneron Pharmaceuticals and gave the stock a “buy” rating in a report on Saturday, February 11th. BMO Capital Markets upped their price objective on Regeneron Pharmaceuticals from $412.00 to $421.00 and gave the stock a “hold” rating in a report on Monday. Cowen and Company reiterated a “hold” rating and issued a $380.00 price objective on shares of Regeneron Pharmaceuticals in a report on Monday. Zacks Investment Research upgraded Regeneron Pharmaceuticals from a “hold” rating to a “buy” rating and set a $416.00 price objective for the company in a report on Thursday, April 27th. Finally, Barclays PLC upped their price objective on Regeneron Pharmaceuticals from $375.00 to $400.00 and gave the stock an “equal weight” rating in a report on Monday, May 8th. One analyst has rated the stock with a sell rating, thirteen have issued a hold rating and twelve have given a buy rating to the stock. The stock has a consensus rating of “Hold” and a consensus price target of $432.21.
In other news, Director Michael S. Brown sold 1,000 shares of Regeneron Pharmaceuticals stock in a transaction that occurred on Wednesday, March 29th. The shares were sold at an average price of $400.00, for a total transaction of $400,000.00. Following the completion of the sale, the director now owns 1,000 shares of the company’s stock, valued at $400,000. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director Michael S. Brown sold 3,000 shares of Regeneron Pharmaceuticals stock in a transaction that occurred on Friday, May 12th. The shares were sold at an average price of $450.00, for a total transaction of $1,350,000.00. Following the sale, the director now directly owns 3,000 shares of the company’s stock, valued at approximately $1,350,000. The disclosure for this sale can be found here. Insiders own 10.40% of the company’s stock.
Regeneron Pharmaceuticals Company Profile
Regeneron Pharmaceuticals, Inc is a biopharmaceutical company that discovers, invents, develops, manufactures and commercializes medicines for the treatment of serious medical conditions. The Company commercializes medicines for eye diseases, high low-density lipoprotein (LDL) cholesterol, and an inflammatory condition and have product candidates in development in other areas, including rheumatoid arthritis, asthma, atopic dermatitis, pain, cancer, and infectious diseases.
Want to see what other hedge funds are holding REGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Regeneron Pharmaceuticals Inc (NASDAQ:REGN).
Receive News & Ratings for Regeneron Pharmaceuticals Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Regeneron Pharmaceuticals Inc and related companies with MarketBeat.com's FREE daily email newsletter.